Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mononuclear cells (Shanghai Changzheng Hospital)
- Development stage
- Unknown
- Lead developer
- Shanghai ChangZheng Hospital
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
This is an investigational autologous cell therapy consisting of bone marrow-derived mononuclear cells (BMMNCs) developed by Shanghai Changzheng Hospital for the treatment of acute traumatic spinal cord injury. The therapy involves harvesting the patient's own bone marrow, isolating the mononuclear cell fraction, and administering them via intrathecal transplantation (lumbar injection) into the spinal canal. The biological mechanism involves the potential of these cells to modulate the spinal microenvironment, provide neurotrophic support, and potentially differentiate into neural cells to promote functional recovery. It is currently being evaluated in a Phase 2 clinical study to assess safety and effectiveness in patients within the acute phase of injury.
- Other names
- Autologous BMMNCsAutologous bone marrow-derived mononuclear cells
Beyond the preview
Go deeper on autologous bone marrow-derived mononuclear cells (Shanghai Changzheng Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mononuclear cells (Shanghai Changzheng Hospital).